Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab by Kirsten I. Taylor, Florian Lipsmeier, Marzia A. Scelsi, Ekaterina Volkova-Volkmar, Daria Rukina, Werner Popp, Stefan Lambrecht, Judith Anzures-Cabrera, David Summers, Markus Abt, Annabelle Monnet, Timothy Kilchenmann, Jens Schjodt-Eriksen, Laurent Essioux, Thomas Kustermann, Wagner Zago, Hanno Svoboda, Tania Nikolcheva, Ronald B. Postuma, Gennaro Pagano, Michael Lindemann, PASADENA Investigators, Prasinezumab Study Group

Get full text

Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease. by Gergely Tóth, Shyra J Gardai, Wagner Zago, Carlos W Bertoncini, Nunilo Cremades, Susan L Roy, Mitali A Tambe, Jean-Christophe Rochet, Celine Galvagnion, Gaia Skibinski, Steven Finkbeiner, Michael Bova, Karin Regnstrom, San-San Chiou, Jennifer Johnston, Kari Callaway, John P Anderson, Michael F Jobling, Alexander K Buell, Ted A Yednock, Tuomas P J Knowles, Michele Vendruscolo, John Christodoulou, Christopher M Dobson, Dale Schenk, Lisa McConlogue

Get full text